Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03048019 · ClinicalTrials.gov registry record
Antiplatelet Effects of Tirofiban vs. Cangrelor N-STEMI Patients Undergoing Percutaneous Coronary Intervention
A clinical trial, sponsored by Inova Health Care Services.
- Terminated
- Registry status
- 10
- Enrollment target
NCT03048019 is a clinical trial that was terminated before completion, run by Inova Health Care Services. The registered enrollment target is 10 participants.
The verdict
NCT03048019 was terminated before completion, sponsored by Inova Health Care Services.
- TERMINATED
- Registry status
- 10 participants
- Enrollment target
Study Summary
Immediate potent inhibition of platelet function is critical for the prevention of periprocedural ischemic event occurrences in high risk N-ST segment elevation myocardial infarction (NSTEMI) in patients undergoing percutaneous coronary intervention (PCI). Currently, dual antiplatelet therapy with aspirin and an oral P2Y12 receptor blocker (with loading doses) is widely used for PCI. However, immediate, potent and reversible inhibition of platelet aggregation is not possible even with the newer oral agents, prasugrel and ticagrelor. Therefore, an intravenously administered GPIIb/IIIa receptor inhibitor (tirofiban) or P2Y12 receptor blocker (cangrelor) with fast onset and offset of actions will provide more desired antiplatelet effects in the setting of PCI. This study will measure and compare the anti-platelet effects of Tirofiban and Cangrelor in patients presenting with N-STEMI and undergoing PCI.
Interventions
- DRUG Tirofiban
- DRUG Cangrelor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-08-23 |
| Est. Completion | 2019-06-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03048019
The ClinicalTrials.gov registry entry for NCT03048019 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inova Health Care Services, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tirofiban is the first listed.
NCT03048019 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03048019 about?
NCT03048019 is a clinical study titled "Antiplatelet Effects of Tirofiban vs. Cangrelor N-STEMI Patients Undergoing Percutaneous Coronary Intervention". Immediate potent inhibition of platelet function is critical for the prevention of periprocedural ischemic event occurrences in high risk N-ST segment elevation myocardial infarction (NSTEMI) in patients undergoing percutaneous coronary intervention (PCI). Currently, dual antiplatelet therapy with a...
What is the current status of trial NCT03048019?
This trial is currently terminated. The enrollment target is 10 participants. The study started on 2017-08-23. Estimated completion is 2019-06-27.
What interventions are being tested in trial NCT03048019?
The interventions under investigation include: Tirofiban (DRUG), Cangrelor (DRUG).
Who is sponsoring clinical trial NCT03048019?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.